About Bioamber (NYSE:BIOA)
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:BIOA
CUSIPN/A
Phone+1-612-7474423
Debt
Debt-to-Equity Ratio0.24%
Current Ratio1.08%
Quick Ratio0.75%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$8.27 million
Price / Sales0.47
Cash FlowN/A
Price / CashN/A
Book Value$1.41 per share
Price / Book0.02
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-22,470,000.00
Net Margins-238.43%
Return on Equity-48.72%
Return on Assets-22.92%
Miscellaneous
Employees86
Outstanding Shares129,450,000
Bioamber (NYSE:BIOA) Frequently Asked Questions
What is Bioamber's stock symbol?
Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."
How were Bioamber's earnings last quarter?
Bioamber Inc (NYSE:BIOA) announced its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to the consensus estimate of $2.37 million. Bioamber had a negative return on equity of 48.72% and a negative net margin of 238.43%. View Bioamber's Earnings History.
When is Bioamber's next earnings date?
What price target have analysts set for BIOA?
2 equities research analysts have issued 1 year target prices for Bioamber's stock. Their predictions range from $1.00 to $1.75. On average, they expect Bioamber's share price to reach $1.3750 in the next twelve months. View Analyst Ratings for Bioamber.
Who are Bioamber's key executives?
Bioamber's management team includes the folowing people:
- Raymond J. Land, Chairman of the Board (Age 72)
- Richard P. Eno, Chief Financial Officer, Director
- Mario Settino, Chief Financial Officer
- Michael A. Hartmann, Executive Vice President (Age 48)
- James Millis, Chief Technology Officer (Age 59)
- Robert Frost, Director
- Kurt W. Briner, Independent Director (Age 70)
- Heinz Haller, Independent Director (Age 62)
- Ellen B. Richstone, Independent Director (Age 65)
- Kenneth W Wall, Independent Director (Age 66)
Has Bioamber been receiving favorable news coverage?
Media stories about BIOA stock have been trending positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioamber earned a media sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.94 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Bioamber?
Shares of BIOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioamber's stock price today?
One share of BIOA stock can currently be purchased for approximately $0.0299.
How big of a company is Bioamber?
Bioamber has a market capitalization of $3.08 million and generates $8.27 million in revenue each year. Bioamber employs 86 workers across the globe.
How can I contact Bioamber?
Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected]
MarketBeat Community Rating for Bioamber (BIOA)
MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote "Outperform" if you believe BIOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bioamber (NYSE:BIOA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Bioamber in the last 12 months. Their average twelve-month price target is $1.3750, suggesting that the stock has a possible upside of 4,498.66%. The high price target for BIOA is $1.75 and the low price target for BIOA is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.67 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.3750 | $6.50 | $6.50 | $3.00 |
| Price Target Upside: | 4,498.66% upside | 1,429.41% upside | 1,429.41% upside | 13.64% upside |
Bioamber (NYSE:BIOA) Consensus Price Target History
Bioamber (NYSE:BIOA) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Bioamber (NYSE:BIOA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Bioamber (NYSE BIOA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 28.70%
Bioamber (NYSE BIOA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/30/2017 | Kenneth W Wall | Director | Buy | 40,000 | $0.43 | $17,200.00 | 170,443 |  |
| 8/18/2017 | Michael A Hartmann | Insider | Buy | 10,000 | $0.48 | $4,800.00 | 153,476 | |
| 8/9/2017 | Mario Settino | CFO | Buy | 15,000 | $0.53 | $7,950.00 | 30,000 | |
| 11/9/2016 | George Frederick John Gosbee | Director | Buy | 25,000 | $3.87 | $96,750.00 | 25,000 | |
| 11/8/2016 | Kurt W Briner | Director | Buy | 10,000 | $3.84 | $38,400.00 | 152,645 | |
| 5/24/2016 | Kurt W Briner | Director | Buy | 1,000 | $3.69 | $3,690.00 | 142,645 | |
| 5/23/2016 | Kurt W Briner | Director | Buy | 21,015 | $3.61 | $75,864.15 | 132,730 | |
| 5/11/2016 | Jean-Francois Huc | CEO | Buy | 10,000 | $3.22 | $32,200.00 | 154,222 | |
| 5/9/2016 | Kenneth W Wall | Director | Buy | 13,227 | $3.11 | $41,135.97 | 31,227 | |
| 5/6/2016 | Michael A Hartmann | EVP | Buy | 3,000 | $3.44 | $10,320.00 | 125,143 | |
| 12/3/2015 | Jean-Francois Huc | CEO | Sell | 27,278 | $8.11 | $221,224.58 | 144,222 | |
| 12/3/2015 | Michael A. Hartmann | EVP | Sell | 21,477 | $8.11 | $174,178.47 | 123,143 | |
| 8/14/2015 | Michael A Hartmann | EVP | Buy | 1,500 | $6.75 | $10,125.00 | | |
| 8/11/2015 | Jean-Francois Huc | CEO | Buy | 4,000 | $6.18 | $24,720.00 | | |
| 8/10/2015 | Raymond J Land | Director | Buy | 1,500 | $6.71 | $10,065.00 | | |
| 5/6/2015 | Jean-Francois Huc | CEO | Buy | 8,800 | $9.00 | $79,200.00 | | |
| 5/6/2015 | Kurt W Briner | Director | Buy | 10,000 | $9.00 | $90,000.00 | | |
| 5/6/2015 | Michael A Hartmann | EVP | Buy | 1,100 | $9.00 | $9,900.00 | | |
| 12/11/2014 | Kenneth W Wall | Director | Buy | 3,000 | $9.20 | $27,600.00 | | |
| 12/10/2014 | Kenneth W Wall | Director | Buy | 5,000 | $9.30 | $46,500.00 | | |
| 11/10/2014 | Kurt W Briner | Director | Buy | 15,000 | $9.35 | $140,250.00 | | |
| 9/9/2014 | Kurt W Briner | Director | Buy | 5,000 | $12.00 | $60,000.00 | | |
| 8/25/2014 | Kurt W Briner | Director | Buy | 14,250 | $11.50 | $163,875.00 | | |
| 8/11/2014 | Kurt W Briner | Director | Buy | 2,980 | $11.45 | $34,121.00 | | |
| 7/16/2014 | Jean-Francois Huc | CEO | Buy | 4,000 | $12.00 | $48,000.00 | | |
| 7/16/2014 | Michael A Hartmann | EVP | Buy | 3,000 | $12.00 | $36,000.00 | | |
| 5/12/2014 | Andrew P Ashworth | CFO | Buy | 3,000 | $10.00 | $30,000.00 | | |
| 5/12/2014 | Michael A Hartmann | EVP | Buy | 2,500 | $10.05 | $25,125.00 | | |
| 11/14/2013 | Kurt W Briner | Director | Buy | 7,200 | $6.95 | $50,040.00 | | |
| 9/3/2013 | Michael A Hartmann | EVP | Buy | 2,000 | $4.63 | $9,260.00 | | |
| 8/29/2013 | Jean-Francois Huc | CEO | Buy | 5,000 | $4.25 | $21,250.00 | | |
| 8/15/2013 | Kurt W Briner | Director | Buy | 13,000 | $5.49 | $71,370.00 | | |
(Data available from 1/1/2013 forward)
Bioamber (NYSE BIOA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Bioamber (BIOA) PT Set at $3.00 by Cowen
www.americanbankingnews.com - April 17 at 10:21 PM |
| Contrasting Sigma-Aldrich (SIAL) and Bioamber (BIOA)
www.americanbankingnews.com - March 30 at 1:16 AM |
| Bioamber (BIOA) Price Target Cut to $1.75 by Analysts at HC Wainwright
www.americanbankingnews.com - March 29 at 12:22 PM |
 | Edited Transcript of BIOA earnings conference call or presentation 28-Mar-18 12:00pm GMT
finance.yahoo.com - March 29 at 8:19 AM |
 | BioAmber's (BIOA) CEO Rick Eno on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 28 at 5:24 PM |
 | BioAmber Inc. Announces Record Revenues for the Fourth Quarter and Year End 2017
www.prnewswire.com - March 27 at 5:19 PM |
| Sigma-Aldrich (SIAL) & Bioamber (BIOA) Critical Analysis
www.americanbankingnews.com - March 17 at 11:24 AM |
| BioAmber, Inc. to Host Earnings Call
finance.yahoo.com - March 16 at 8:13 AM |
| Aqua Concept GmbH Launches coracon® LT EKO, a Performing and Sustainable Heat Transfer Fluid Engineered from BioAmber's Bio Succinic Acid
finance.yahoo.com - March 13 at 8:17 AM |
| BioAmber Announces Webcast of Fiscal Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 12 at 6:44 PM |
| Bioamber (BIOA) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:32 AM |
| Bioamber (BIOA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 4 at 11:06 PM |
 | Form 25-NSE BioAmber Inc. Filed by: NEW YORK STOCK EXCHANGE LLC - StreetInsider.com
www.streetinsider.com - February 28 at 8:12 AM |
| BioAmber, Product Development, Financial Review, TSX Issue, Analysts Target
finance.yahoo.com - February 26 at 5:48 PM |
| Form SC 13G BioAmber Inc. Filed by: INTRACOASTAL CAPITAL, LLC - StreetInsider.com
www.streetinsider.com - February 20 at 8:13 AM |
| Bioamber (BIOA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 19 at 6:58 PM |
| BioAmber Inc. Receives Notice of Delisting by TSX - PR Newswire (press release)
www.prnewswire.com - February 18 at 8:14 AM |
| BioAmber Inc. Receives Notice of Delisting by TSX
finance.yahoo.com - February 16 at 8:13 AM |
| Bioamber (BIOA) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - February 14 at 11:42 PM |
| BioAmber Inc. Receives Notice of Delisting Review by TSX
finance.yahoo.com - February 14 at 9:18 AM |
| Bioamber (BIOA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 13 at 7:00 PM |
| BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering
finance.yahoo.com - February 9 at 3:50 PM |
 | BRIEF-Bioamber Inc Announces Pricing Of US$10 Mln Underwritten Public Offering
www.reuters.com - February 6 at 8:49 AM |
| Is BioAmber Inc (NYSE:BIOA) A Financially Sound Company?
finance.yahoo.com - February 6 at 8:49 AM |
| BioAmber Inc. announces underwritten offering
finance.yahoo.com - February 6 at 8:49 AM |
| BioAmber Inc. Announces Pricing of US$10 Million Underwritten Public Offering
finance.yahoo.com - February 6 at 8:49 AM |
| Bioamber (BIOA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 31 at 6:40 PM |
| Bio-Succinic Acid Demonstrates Substantial Benefits Toward Growth Performance in Animal Feed Commercial Trial
finance.yahoo.com - January 29 at 9:10 AM |
| BRIEF-Bioamber Restructures Its Credit Facility With Its Senior Lenders - Reuters
www.reuters.com - January 27 at 3:42 PM |
| BioAmber (BIOA) Canadian Subsidiary Restructures Credit Facility - StreetInsider.com
www.streetinsider.com - January 27 at 3:42 PM |
| Contrasting Chemtura (CHMT) and Bioamber (BIOA)
www.americanbankingnews.com - January 27 at 11:26 AM |
| BioAmber restructures its credit facility with its senior lenders
finance.yahoo.com - January 26 at 8:43 AM |
 | Global Renewable Chemicals Industry
www.bizjournals.com - January 19 at 9:52 AM |
| Zacks: Analysts Set $6.50 Price Target for Bioamber Inc (BIOA)
www.americanbankingnews.com - January 12 at 9:32 AM |
| Bioamber (BIOA) & AdvanSix (ASIX) Critical Analysis
www.americanbankingnews.com - January 9 at 11:16 PM |
| Bioamber (BIOA) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 5:40 PM |
| North America organic acid market is projected to reach $ 3,043.5 million by 2026
www.bizjournals.com - January 5 at 8:23 AM |
| Bioamber (BIOA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 3 at 12:06 AM |
| With A -20.78% Earnings Drop Lately, Did BioAmber Inc (NYSE:BIOA) Underperform Its Industry?
finance.yahoo.com - January 2 at 3:31 PM |
| Stock Review for Chemicals Investors -- BioAmber, Air Products and Chemicals, Celanese, and Eastman Chemical ... - PR Newswire (press release)
www.prnewswire.com - December 18 at 8:04 AM |
| Brokerages Set $6.50 Price Target for Bioamber Inc (BIOA)
www.americanbankingnews.com - December 13 at 9:18 PM |
| Bioamber Inc (BIOA) Director Acquires $17,200.00 in Stock
www.americanbankingnews.com - December 4 at 9:32 PM |
| Bioamber (BIOA) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 3 at 10:04 PM |
 | Global Tetrahydrofuran (THF) Markets, 2024: Increasing Focus on Green Chemistry: A Strong Growth Driver for 2-MeTHF
www.finanznachrichten.de - November 23 at 3:45 PM |
| Contrasting Trinseo (TSE) & BioAmber (BIOA)
www.americanbankingnews.com - November 23 at 3:12 AM |
| BioAmber Inc. (BIOA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 17 at 7:12 PM |
| Short Interest in BioAmber Inc. (BIOA) Expands By 111.4%
www.americanbankingnews.com - November 16 at 1:34 AM |
| Edited Transcript of BIOA earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 11 at 9:26 PM |
| BioAmber Inc. (BIOA) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 11 at 10:22 AM |
| HC Wainwright Reiterates "Buy" Rating for BioAmber Inc. (BIOA)
www.americanbankingnews.com - November 8 at 11:10 PM |
Bioamber (NYSE:BIOA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bioamber (NYSE:BIOA) Income Statement, Balance Sheet and Cash Flow Statement
Bioamber (NYSE BIOA) Stock Chart for Thursday, April, 26, 2018
Loading chart…
